{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:26:12Z","timestamp":1781180772714,"version":"3.54.1"},"reference-count":42,"publisher":"Informa UK Limited","issue":"14","funder":[{"name":"National Institute on Drug"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Substance Use & Misuse"],"published-print":{"date-parts":[[2020,11,2]]},"DOI":"10.1080\/10826084.2020.1817082","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T06:10:44Z","timestamp":1599891044000},"page":"2364-2370","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Factors Associated with Gabapentin Misuse among People Who Inject Drugs in Appalachian Kentucky"],"prefix":"10.1080","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5001-7391","authenticated-orcid":false,"given":"Mance E.","family":"Buttram","sequence":"first","affiliation":[{"name":"Center for Applied Research on Substance Use and Health Disparities, Nova Southeastern University, Miami, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilary L.","family":"Surratt","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science, College of Medicine, University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"CIT0001","unstructured":"Alabama State Board of Health. (2019). Controlled substances list. Retrieved February 7, 2020, from https:\/\/www.alabamapublichealth.gov\/publications\/assets\/controlledsubstanceslist.pdf"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1007\/s11121-014-0500-4"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.01.024"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1159\/000355268"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1007\/s11126-016-9421-7"},{"issue":"5","key":"CIT0006","volume":"17","author":"Berlin R. K.","year":"2015","journal-title":"The Primary Care Companion for CNS Disorders"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2019.106172"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.2165\/11536200-000000000-00000"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1080\/13645579.2013.811921"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107554"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4230"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2019.07.011"},{"key":"CIT0013","unstructured":"Centers for Disease Control and Prevention. (2020). U.S. opioid prescribing rate maps. Retrieved May 2, 2020, from https:\/\/.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.06.005"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-017-0112-7"},{"key":"CIT0016","volume-title":"Global appraisal of individual needs\u2013 short screener (GAIN-SS): Administration and Scoring Manual, Version 3","author":"Dennis M. L.","year":"2013"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.06.018"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0700-x"},{"key":"CIT0019","volume-title":"Global appraisal of individual needs \u2013 Indivdiual (GAIN-I), version [GVER]: 5.7.6","author":"Global Appraisal of Individual Needs","year":"2016"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1704633"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.2307\/3096941"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2011.07.046"},{"key":"CIT0023","unstructured":"King, L. (2020). State-imposed restrictions on gabapentin. Retrieved February 7, 2020, from, https:\/\/www.medval.com\/2020\/01\/08\/state-imposed-restrictions-on-gabapentin\/"},{"key":"CIT0024","unstructured":"Michigan Department of Licensing and Regulatory Affairs. (2019). Gabapentin scheduled as controlled substance to help with state's opioid epidemic. Retrieved February 28, 2019, from https:\/\/www.michigan.gov\/lara\/0,4601,7-154-11472-487050\u2013,00.html"},{"key":"CIT0025","unstructured":"Mincher, T. (2018). Gabapentin is a Schedule V controlled substance as of July 1, 2018. Tennessee Veterinary Medical Association. Retrieved January 29, 2020, from http:\/\/tvmanet.com\/2018\/06\/29\/gabapentin-is-a-schedule-v-controlled-substance-as-of-july-1-2018\/"},{"key":"CIT0026","unstructured":"North Dakota State Board of Pharmacy. (2019). Gabapentin added as a Schedule V substance in the North Dakota Controlled Substanced Act. Retrieved February 7, 2020, from https:\/\/nabp.pharmacy\/wp-content\/uploads\/2016\/06\/North-Dakota-Newsletter-June-2019.pdf"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.04.004"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-011-0032-x"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.26.3.246"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S168504"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1177\/1178221818801311"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.7326\/L19-0155"},{"key":"CIT0033","unstructured":"Quintiles IMS Institute (2017). Medicines use and spending in the U.S.: A review of 2016 and outlook to 2021. Retrieved December 4, 2019, from https:\/\/structurecms-staging-psyclone.netdna-ssl.com\/client_assets\/dwonk\/media\/attachments\/590c\/6aa0\/6970\/2d2d\/4182\/0000\/590c6aa069702d2d41820000.pdf?1493985952"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.13111526"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.14101272"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1111\/jrh.12256"},{"key":"CIT0037","unstructured":"U.S. Food and Drug Administration. (2019). FDA in brief: FDA requires new warnings for gabapentinoids about risk of respiratory depression. Retrieved May 2, 2020, from https:\/\/www.fda.gov\/news-events\/fda-brief\/fda-brief-fda-requires-new-warnings-gabapentinoids-about-risk-respiratory-depression"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1037\/adb0000337"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.107709"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.2217\/pmt.13.62"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.21897"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12159"}],"container-title":["Substance Use & Misuse"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10826084.2020.1817082","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T20:59:04Z","timestamp":1620593944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10826084.2020.1817082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":42,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2020,11,2]]}},"alternative-id":["10.1080\/10826084.2020.1817082"],"URL":"https:\/\/doi.org\/10.1080\/10826084.2020.1817082","relation":{},"ISSN":["1082-6084","1532-2491"],"issn-type":[{"value":"1082-6084","type":"print"},{"value":"1532-2491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=isum20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}